- 作者：Inkeun Park ; Kwonoh Park ; Seongjoon Park ; Yongcheol Ahn ; Jin-Hee Ahn ; Hyuck Jae Choi ; In Gab Jeong ; Cheryn Song ; Jun Hyuk Hong ; Choung-Soo Kim ; Hanjong Ahn ; Jae-Lyun Lee
- 关键词：Primary lesion ; RCC ; RECIST ; Sunitinib ; Target lesion
- 刊名：Clinical Genitourinary Cancer
- 出版年：2013
- 出版时间：September, 2013
- 年：2013
- 卷：11
- 期：3
- 页码：276-282
- 全文大小：453 K
Background
We evaluated whether best overall response changes by designating primary renal lesions as either target or nontarget lesions and assessing response per Response Evaluation Criteria in Solid Tumors in mRCC patients treated with sunitinib. In addition, we evaluated whether discordance, if any, leads to a difference in predictive value of response in terms of time to progression (TTP) and overall survival (OS).Patients and Methods
Patients with mRCC with an intact primary tumor and at least 1 extrarenal measurable lesion were included in this study. The variation of the sum of diameters (¦¤SOD) of target lesions and best overall response, assessed from all target lesions and from metastasis-only target lesions, was documented separately.
Results
There were 41 patients included. Median ¦¤SOD of the primary lesion and metastatic target lesion were ?6.0 % (range, ?34.0 % to 17.6 % ), and ?18.0 % (range, ?100.0 % to 120.0 % ), respectively. For metastasis-only target lesions, the best overall response of 2 patients (4.9 % ) changed from stable disease to partial response. When we categorized patients into responders and nonresponders, response determination using metastasis-only target lesions resulted in significantly better discrimination of time to progression (14.9 vs. 4.3 months,
Conclusion
When treating nonnephrectomized mRCC patients, selecting metastasis-only lesions as target lesions might be better to determine response, which might be more representative of survival end point.